Cholestin Red Yeast Rice Shipments Halted Pending FDA Talks
This article was originally published in The Tan Sheet
Executive Summary
Pharmanex suspended U.S. shipments of Cholestin April 2 following a federal court decision affirming FDA's determination that the red yeast rice product is a drug, not a dietary supplement.
You may also be interested in...
Questions Circle INDs; Industry Needs Guidance For Probiotics, Say Experts
FDA should consider issuing a guidance for probiotics similar to the 2004 industry guidance for botanical drugs, panelists said at a recent Drug Information Association conference
Linnea
New Melilotus (yellow sweet clover) extract for "venous system" support contains coumarin, "the active ingredient in blood-thinning prescription drugs such as Coumadin," according to Swiss-based extract supplier. Linnea, which is introducing the extract to U.S. supplement market, says it has not spoken with FDA regarding whether agency might consider ingredient a "new drug." Cholestin maker Pharmanex removed red yeast rice from its products following court ruling affirming FDA's determination it contains the same active ingredient as Merck's cholesterol-lowering drug Mevacor (1"The Tan Sheet" April 9, p. 3)...
Red Yeast Rice Enforcement Actions, Product Withdrawals Underway
FDA is stepping up enforcement activity against red yeast rice product manufacturers and marketers in the wake of a Utah federal judge's recent decision finding the ingredient to be a drug, not a dietary supplement.